- OHE - Page 2

It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?

Read more

Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making

Read more

Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies

Read more

Exploring the Financial Sustainability of Gene Therapies

Read more

© Sergey Nivens

Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective

Read more

Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology

Read more

Cornerstones of “Fair” Drug Coverage: Appropriate Cost – Sharing and Utilization Management Policies for Pharmaceuticals

Read more

How Should the World Pay for a COVID-19 Vaccine?

Read more

© Daniel Schludi/Unsplash

A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold

Read more

Indication-Based Pricing (IBP) Consultation Report

Read more

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Read more

Data Governance Arrangements for Real-World Evidence in Japan

Read more

The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK

Read more

Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?

Read more

Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?

Read more

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment

Read more

01
02
03
04
05
06
00